Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: Retrospective immunohistochemical study

Croatian Medical Journal

Volumn 52, Issue 2, 2011, Pages 171-177

  Matković, Božica ^a   Juretić, Antonio ^b   Spagnoli, Giulio C ^c   Šeparović, Viktor ^a   Gamulin, Marija ^d   Šeparović, Robert ^a   Šarić, Nera ^d   Bašić Koretić, Martina ^d   Novosel, Irena ^e   Krušlin, Božo ^b  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e Dr Ivo Pedi i General Hospital   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; PARAFFIN; PROTEIN MAGE A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROATIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; CROATIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79959649588     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2011.52.171     Document Type: Article

References (41)

1. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B. The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia. 2000;5:139-63.
2. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009;59:303-13.
3. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117:3155-63.
4. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718-30.
5. Bosch A, Eroles P, Zaragoza R, Vińa JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206-15.
6. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365-85.
7. Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol. 2003;27:832-5.
8. Eichhorn JH. Medullary carcinoma, provocative now as then. Semin Diagn Pathol. 2004;21:65-73.
9. Milde S, Gaedcke J, v Wasielewski R, Bruchardt H, Wingen L, Gadzicki D, et al. Diagnosis and immunohistochemistry of medullary breast cancer [in German]. Pathologe. 2006;27:358-62.
10. Malyuchik SS, Kiyamova RG. Medullary breast carcinoma. Exp Oncol. 2008;30:96-101.
11. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-50.
12. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma-rare types: review of the literature. Ann Oncol. 2009;20:1763-70.
13. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer. 2009;45:1780-7.
14. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260-8.
15. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636-44.
16. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, Sarrio D, Martin-Guijarro Mdel C, Hernandez L, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol. 2007;31:501-8.
17. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24.
18. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-7.
19. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 2003;4:104-9.
20. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-25.
21. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2007;25:707-11.
22. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008;105:20422-7.
23. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100:2014-21.
24. Kavalar R, Sarcevic B, Spagnoli GC, Separovic V, Samija M, Terracciano L, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch. 2001;439:127-31.
25. Bandic D, Juretic A, Sarcevic B, Separovic V, Kujundzic-Tiljak M, Hudolin T, et al. Expression and possible prognostic role of MAGEA4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J. 2006;47:32-41.
26. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer. 2006;118:696-703.
27. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A. 2009;106:13493-8.
28. Matkovic B, Juretic A, Separovic V, Novosel I, Separovic R, Gamulin M, et al. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori. 2008;94:838-44.
29. Schultz-Thater E, Juretic A, Dellabona P, Luscher U, Siegrist W, Harder F. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer. 1994;59:435-9.
30. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995;55:2236-9.
31. Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer. 2000;83:204-8.
32. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, et al. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol. 2011;22:98-103.
33. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg. 2002;236:785-93.
34. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer. 2002;100:702-5.
35. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res. 2003;9:6453-60.
36. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol. 2008;198:99.e1-7.
37. Jung EJ, Kim MA, Lee HS, Yang HK, Lee YM, Lee BL, et al. Expression of family A melanoma antigen in human gastric carcinoma. Anticancer Res. 2005;25:2105-11.
38. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene. 2003;22:6484-8.
39. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics. 2006;1:116-20.
40. Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E, Maio M. Epigenetic remodelling of DNA in cancer. Histol Histopathol. 2007;22:1413-24.
41. Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, Chang SS, et al. Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS ONE. 2009;4:e8189.